On Mar. 23, 2020, Cumberland Pharmaceuticals announced a national initiative to support the treatment of patients with hospital-acquired and ventilator-associated pneumonia associated with the outbreak of the COVID-19 coronavirus.

Cumberland’s initiative included the availability of special financial arrangements for hospitals and clinics to help ensure supply during this unprecedented healthcare crisis. In addition, Cumberland sponsored a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from the novel coronavirus.